Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, and the like has, of course, returned. The world, after all, keeps spinning, yes? Not surprisingly, our response is to fire up the coffee kettle and prepare a few cups of stimulation. Feel free to join us. Remember, no prescription is required, so no mysterious rebates are involved. Meanwhile, here are a few tidbits to help you along. Hope your day is smashing and do stay in touch. …

The Japanese health ministry warned that the Lilly (LLY) breast cancer drug called Verzenio is suspected of adversely affecting the lungs after 14 patients developed a serious lung disease, The Japan Times reports. The drug is suspected of causing the side effects in at least four of the 14 cases, including one fatality. The drug received Japanese clearance last September and debuted in November. The number of patients in Japan who have used the oral drug since its release is estimated at around 2,000.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy